Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Jun 11, 2016

Successful Switch to Sanofi's Toujeo® Evaluated in a Real-World Setting
Jun 6, 2016

Sanofi and Regeneron Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients

- These data, along with previous Phase 3 studies, will be part of a U.S. regulatory submission for dupilumab, which is on track for Q3 of 2016 -
May 25, 2016

FDA Advisory Committee Recommends Approval of Sanofi Treatment for Adults with Type 2 Diabetes

- FDA decisions on the investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide and investigational lixisenatide anticipated in Q3 2016 -
Apr 29, 2016

Solid Performance in the First Quarter of 2016 with Business EPS up 5.3% at Constant Exchange Rates
- Photos 1
Apr 27, 2016

Sanofi US Collaborates with Duke University and Massachusetts General Hospital on Big Data and Type 2 Diabetes

- Collaborations Will Work towards Predicting Medication Adherence -
- Photos 1
Mar 16, 2016

Sanofi and Regeneron Strongly Disagree with U.S. Jury Verdict in Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection and Will Appeal
Feb 22, 2016

FDA Accepts Sanofi New Drug Application for Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide

- FDA decision anticipated in August 2016 -
Feb 12, 2016

ACT® Advanced Care™ Mouthwash Named 2016 Product of the Year

America's Leading National Consumer Research Survey Ranks ACT Advanced Care #1 in "Oral Care" Category
Feb 9, 2016

Sanofi Delivered 2015 Business EPS up 8.5% on a Reported Basis and Stable at Constant Exchange Rates Consistent with Guidance
- Photos 1
Feb 2, 2016

Sanofi and Regeneron Announce Publication of Positive Phase 2 Dupilumab Data in the Journal of the American Medical Association

Study Evaluated Adult Patients with Chronic Sinusitis with Nasal Polyposis who did not Respond to Intranasal Corticosteroids

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.